HLS Therapeutics Inc.
HLS.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 12.86M | 15.20M | 13.51M | 14.17M | 12.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.86M | 15.20M | 13.51M | 14.17M | 12.62M |
| Cost of Revenue | 4.19M | 4.28M | 3.81M | 3.87M | 3.83M |
| Gross Profit | 8.67M | 10.92M | 9.70M | 10.30M | 8.79M |
| SG&A Expenses | 5.35M | 5.22M | 5.57M | 5.60M | 5.62M |
| Depreciation & Amortization | 5.54M | 5.46M | 5.51M | 5.48M | 5.36M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.08M | 14.96M | 14.89M | 14.95M | 14.81M |
| Operating Income | -2.22M | 237.00K | -1.37M | -778.00K | -2.19M |
| Income Before Tax | -2.30M | -1.98M | -3.94M | -2.50M | -4.46M |
| Income Tax Expenses | 2.00K | -647.00K | -17.00K | 242.00K | -23.00K |
| Earnings from Continuing Operations | -2.30M | -1.34M | -3.92M | -2.74M | -4.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.30M | -1.34M | -3.92M | -2.74M | -4.44M |
| EBIT | -2.22M | 237.00K | -1.37M | -778.00K | -2.19M |
| EBITDA | 3.32M | 5.18M | 4.14M | 4.71M | 3.17M |
| EPS Basic | -0.07 | -0.04 | -0.12 | -0.09 | -0.14 |
| Normalized Basic EPS | -0.05 | -0.04 | -0.08 | -0.05 | -0.09 |
| EPS Diluted | -0.07 | -0.04 | -0.12 | -0.09 | -0.14 |
| Normalized Diluted EPS | -0.05 | -0.04 | -0.08 | -0.05 | -0.09 |
| Average Basic Shares Outstanding | 31.27M | 33.38M | 31.40M | 31.64M | 31.79M |
| Average Diluted Shares Outstanding | 31.27M | 33.38M | 31.40M | 31.64M | 31.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |